Zealand Pharma AS 2016 AR2
The report highlights Zealand Pharma's significant progress in 2016, transitioning toward becoming a fully integrated biotechnology company. Key achievements included the U.S. FDA approvals of Adlyxin and Soliqua 100/33, which triggered substantial milestone payments and established growing royalty streams. The company advanced its clinical pipeline, notably progressing Phase 2 trials for glepaglutide in short bowel syndrome and dasiglucagon for severe hypoglycemia. Zealand also established a key collaboration with Beta Bionics for a dual-hormone artificial pancreas system. Financially, the company reported a 25% revenue increase to DKK 234.8 million, supported by a strong year-end cash position of DKK 642 million.
Company: Zealand Pharma AS
Sector: Health Care
Country: Denmark
Year: 2016
Type: AR2
Pages: 84
Zealand Pharma AS
Annual Report
The report highlights Zealand Pharma's significant progress in 2016, transitioning toward becoming a fully integrated biotechnology company. Key achievements included the U.S. FDA approvals of Adlyxin and Soliqua 100/33, which triggered substantial milestone payments and established growing royalty streams. The company advanced its clinical pipeline, notably progressing Phase 2 trials for glepaglutide in short bowel syndrome and dasiglucagon for severe hypoglycemia. Zealand also established a key collaboration with Beta Bionics for a dual-hormone artificial pancreas system. Financially, the company reported a 25% revenue increase to DKK 234.8 million, supported by a strong year-end cash position of DKK 642 million.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Employees